Abstract：
BACKGROUND: Psoriasis is an autoimmune disease characterized by dysfunctional T cells and dysregulated immune responses. Smilax glabra Roxb. (SGR) is a formulation used in Traditional Chinese Medicine for the treatment of inflammatory skin disorders, including psoriasis. This study explores the scientific basis for its use by examining the effects of SGR on T cell differentiation and insulin receptor signaling, relevant pathways implicated in the pathophysiology of psoriasis.
OBJECTIVE: This study investigates the therapeutic potential of SGR (a Chinese medicine) in psoriasis and its impact on T cell differentiation.
METHODS: An integrated network pharmacology and bioinformatics approach was employed to elucidate the mechanisms of SGR in regulating T cell differentiation. A psoriasis mouse model was utilized to evaluate the effects of SGR on T cell subsets. Immunohistochemistry and gene expression analyses were conducted to investigate the modulation of insulin receptor signaling pathways by SGR.
RESULTS: SGR treatment effectively reset the expression of various T cell subsets in the psoriasis mouse model, suggesting its ability to regulate T cell differentiation and immune function. Furthermore, SGR treatment inhibited insulin receptor signaling and downstream pathways, including PI3K/AKT and ERK, in psoriatic skin lesions. This indicates that SGR may exert its therapeutic effects through modulation of the insulin receptor signaling pathway.
CONCLUSIONS: This study provides novel insights into the therapeutic potential of SGR in psoriasis. By modulating T cell differentiation and targeting the insulin receptor signaling pathway, SGR holds promise as a potential treatment option for psoriasis.
OBJECTIVE: This study investigates the therapeutic potential of SGR (a Chinese medicine) in psoriasis and its impact on T cell differentiation.
METHODS: An integrated network pharmacology and bioinformatics approach was employed to elucidate the mechanisms of SGR in regulating T cell differentiation. A psoriasis mouse model was utilized to evaluate the effects of SGR on T cell subsets. Immunohistochemistry and gene expression analyses were conducted to investigate the modulation of insulin receptor signaling pathways by SGR.
RESULTS: SGR treatment effectively reset the expression of various T cell subsets in the psoriasis mouse model, suggesting its ability to regulate T cell differentiation and immune function. Furthermore, SGR treatment inhibited insulin receptor signaling and downstream pathways, including PI3K/AKT and ERK, in psoriatic skin lesions. This indicates that SGR may exert its therapeutic effects through modulation of the insulin receptor signaling pathway.
CONCLUSIONS: This study provides novel insights into the therapeutic potential of SGR in psoriasis. By modulating T cell differentiation and targeting the insulin receptor signaling pathway, SGR holds promise as a potential treatment option for psoriasis.
摘要：
背景：银屑病是一种自身免疫性疾病，其特征是T细胞功能失调和免疫反应失调。SmilaxglabraRoxb.（SGR）是一种用于治疗炎症性皮肤病的中药制剂，包括牛皮癣。本研究通过研究SGR对T细胞分化和胰岛素受体信号传导的影响，探索其使用的科学依据。与银屑病病理生理有关的相关通路。
目的：本研究探讨SGR（中药）在银屑病中的治疗潜力及其对T细胞分化的影响。
方法：采用整合的网络药理学和生物信息学方法阐明SGR调节T细胞分化的机制。使用牛皮癣小鼠模型来评估SGR对T细胞亚群的影响。进行免疫组织化学和基因表达分析以研究SGR对胰岛素受体信号通路的调节。
结果：SGR治疗可有效重置银屑病小鼠模型中各种T细胞亚群的表达，提示其调节T细胞分化和免疫功能的能力。此外，SGR治疗抑制胰岛素受体信号和下游通路，包括PI3K/AKT和ERK,牛皮癣皮肤病变。这表明SGR可能通过调节胰岛素受体信号通路发挥其治疗作用。
结论：这项研究为SGR在银屑病中的治疗潜力提供了新的见解。通过调节T细胞分化和靶向胰岛素受体信号通路,SGR有望成为牛皮癣的潜在治疗选择。
目的：本研究探讨SGR（中药）在银屑病中的治疗潜力及其对T细胞分化的影响。
方法：采用整合的网络药理学和生物信息学方法阐明SGR调节T细胞分化的机制。使用牛皮癣小鼠模型来评估SGR对T细胞亚群的影响。进行免疫组织化学和基因表达分析以研究SGR对胰岛素受体信号通路的调节。
结果：SGR治疗可有效重置银屑病小鼠模型中各种T细胞亚群的表达，提示其调节T细胞分化和免疫功能的能力。此外，SGR治疗抑制胰岛素受体信号和下游通路，包括PI3K/AKT和ERK,牛皮癣皮肤病变。这表明SGR可能通过调节胰岛素受体信号通路发挥其治疗作用。
结论：这项研究为SGR在银屑病中的治疗潜力提供了新的见解。通过调节T细胞分化和靶向胰岛素受体信号通路,SGR有望成为牛皮癣的潜在治疗选择。
